'Hiv rna' presentation slideshows

Principles of Antiretroviral Therapy

Principles of Antiretroviral Therapy . Christopher Behrens, MD Northwest AIDS Education & Training Center University of Washington. CBB/2002. Current Treatment Strategies. DHHS Guidelines regarding when to initiate antiretroviral therapy Adherence Strategic antiretroviral combinations

1.92k views • 100 slides

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. About this Presentation. These slides were developed using the November 2004 Pediatric Guidelines. The intended audience is clinicians involved in the care of patients with HIV.

778 views • 63 slides

Catia Marzolini Division of Infectious Diseases & Hospital Epidemiology

CNS pharmacology of antiretroviral drugs and relevant interactions between antiretroviral and CNS drugs. Catia Marzolini Division of Infectious Diseases & Hospital Epidemiology www.hiv-druginteractions.org. Presentation outline.

850 views • 54 slides

Statistical Science Issues in Preventive HIV Vaccine Efficacy Trials: Part II

Statistical Science Issues in Preventive HIV Vaccine Efficacy Trials: Part II Outline Efficacy Trial Objectives Phase IIb vs Phase III Scientific questions Approaches to the questions HIV infection endpoint Post-infection endpoints Correlates of protective immunity

955 views • 51 slides

The PEARLS Study: A Multinational Clinical Trial of HIV Treatment

The PEARLS Study: A Multinational Clinical Trial of HIV Treatment. P rospective E valuation of A ntiretrovirals in R esource L imited S ettings. Worldwide HIV Prevalence (2001). UNAIDS 2001.

616 views • 44 slides

Principles of HIV Therapy Simple is Better!

Principles of HIV Therapy Simple is Better!. Adeel A. Butt, MD Assistant Professor of Medicine and Infectious Diseases University of Pittsburgh Director, VAPHS HIV-ID Clinics Center for Health Equity Research and Promotion. Member of Academic Research Council

482 views • 36 slides

MONOTERAPIA CON DARUNAVIR/RITONAVIR

754 views • 35 slides

Investigational Approaches to Antiretroviral Therapy

Investigational Approaches to Antiretroviral Therapy. Eric S. Daar, M.D. Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles, California.

531 views • 33 slides

HIV Testing and Prophylaxis to Prevent Mother-to-Child Transmission in the United States

HIV Testing and Prophylaxis to Prevent Mother-to-Child Transmission in the United States. Ma. Teresa C. Ambat, MD Asst Professor TTUHSC-Neonatology 12/2/2008. Introduction.

676 views • 29 slides

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI. Antiretroviral (ARV) Therapy in Adults and Children. Similar pathogenesis of HIV infection General virologic and immunologic principals for antiretroviral therapy apply

528 views • 29 slides

HIV & AIDS

HIV & AIDS. Dr Sat Das Associate Professor Lead Consultant Physician, HIV / GUM University Hospitals Coventry & Warwickshire. Topics. What is AIDS and what is HIV Epidemiology of HIV Natural course of HIV Transmission of HIV Treatment of HIV: What is HAART and how it works

746 views • 28 slides

Immune Activation, HIV Persistence, and the Cure

Immune Activation, HIV Persistence, and the Cure. Daniel C. Douek , MD, PhD Bethesda, Maryland. What We Talk About When We Talk About Immune Activation. Immune activation occurs early in infection. Virus load. Cytokine. A.R. Stacey et al JV 2009.

443 views • 24 slides

RESIST Trials - Grade 3 or 4 AST, ALT or Total Bilirubin: Actions and Outcomes

RESIST Trials - Grade 3 or 4 AST, ALT or Total Bilirubin: Actions and Outcomes. Use of Lipid Lowering Drugs in RESIST. Percentage. n=108. n=102. n=130. n=79. n=238. n=181. Lipid Lowering Agent Use Among RESIST Participants.

1.05k views • 19 slides

XIX International AIDS Conference 2012 Washington DC, USA, 22-27 July, 2012

XIX International AIDS Conference 2012 Washington DC, USA, 22-27 July, 2012 B40: Clinical trials and antiretroviral therapy in children and adolescents. IMPAACT P1066: Raltegravir (RAL) safety and efficacy in HIV infected (+) youth 2 to 18 years of age through week 48.

339 views • 19 slides

At the Heart of Longevity Cardiovascular Health

At the Heart of Longevity Cardiovascular Health. A good head and a good heart are always a formidable combination Nelson Mandela Founder of The Elders ( www.theelders.org ) . Peter Reiss Director HIV Monitoring Foundation Professor of Medicine

308 views • 16 slides

Incorporation of NAT into supplemental testing of HCV and HIV seroreactive donors

Incorporation of NAT into supplemental testing of HCV and HIV seroreactive donors. Michael P. Busch representing Blood Systems Research Institute Blood Systems Laboratories University of California, San Francisco BPAC, Sept., 2003.

281 views • 15 slides

HIV-1 dynamics Perelson et.al. Science 271:1582 (1996)

HIV-1 dynamics Perelson et.al. Science 271:1582 (1996). Latently Infected CD4 + lymphocytes. Infected CD4 + lymphocytes. < 1%. > 99%. CD4 + lymphocytes - defective virus. t 1/2 - 1.6 days. t 1/2 - 6 hrs. < 1%. HIV-1. Long lived cell populations. Uninfected, activated

285 views • 15 slides

Acute HIV Follow-Up in NC Presented by

208 views • 13 slides

Comparison of INSTI vs PI

296 views • 8 slides

Response to combination antiretroviral therapy (cART): variation by age

6-12. 13-17. 18-29. 30-39. 40-49. 50-54. 55-59. >60. 6-12. 13-17. 18-29. 30-39. 40-49. 50-54. 55-59. >60. Age group (years). Age group (years). <2. 2-5. 6-12. 13-17. 18-29. 30-39. 40-49. 50-54. 55-59. >60. Age group (years). COHERE.

162 views • 1 slides